Can my relative be treated with Humira (adalimumab) for their autoimmune condition, and what dosing, screening, and monitoring are required?

Humira (Adalimumab) for Your Relative

Yes, your relative can likely be treated with Humira (adalimumab) if they have a qualifying autoimmune condition, but this requires specific pre-treatment screening and ongoing monitoring to ensure safety.

FDA-Approved Indications

Humira is approved for multiple autoimmune conditions 1:

• Rheumatoid arthritis (adults)
• Psoriatic arthritis (adults)
• Ankylosing spondylitis (adults)
• Moderate-to-severe plaque psoriasis (adults)
• Crohn's disease (adults and children ≥6 years)
• Ulcerative colitis (adults and children ≥5 years)
• Juvenile idiopathic arthritis (children ≥2 years)
• Hidradenitis suppurativa (≥12 years)
• Non-infectious uveitis (adults and children ≥2 years)

Standard Dosing Regimens

For Psoriasis

The recommended dosing is 80 mg subcutaneously at week 0, followed by 40 mg at week 1, then 40 mg every other week thereafter 2, 1. Some patients may benefit from weekly 40 mg dosing for better disease control 2.

For Rheumatoid/Psoriatic Arthritis

40 mg every other week subcutaneously 1. Patients not on methotrexate may benefit from 40 mg weekly or 80 mg every other week 1.

For Crohn's Disease (Adults)

160 mg on Day 1 (can split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29 3, 1.

For Ulcerative Colitis (Adults)

160 mg on Day 1,80 mg on Day 15, then 40 mg every other week starting Day 29 1.

Mandatory Pre-Treatment Screening

Before starting Humira, your relative MUST undergo:

Tuberculosis Screening

• Tuberculin skin test (TST) or interferon-gamma release assay (IGRA) 4, 5
• Chest X-ray 4, 6
• In BCG-vaccinated populations, combined TST/IGRA testing may reduce missed cases 5
• Consider endemic fungal infection risk (histoplasmosis, blastomycosis, coccidioidomycosis) if living in or traveling to endemic areas 6

Hepatitis Screening

• Hepatitis B surface antigen, core antibody, and surface antibody 4, 6
• Hepatitis C antibody 4
• Hepatitis B reactivation can occur with TNF inhibitors 4

Baseline Laboratory Tests

• Complete blood count (CBC) 4
• Liver function tests (LFTs) 4
• Lipid panel if using JAK inhibitors concurrently 3

Medical History Assessment

Look specifically for:

• Active infections (absolute contraindication) 4, 1
• Multiple sclerosis or demyelinating diseases (contraindication) 4, 7, 8
• First-degree relatives with MS (strong contraindication—sibling relative risk 18-36) 4
• Congestive heart failure (NYHA class III/IV is contraindication; class I/II requires echocardiogram with ejection fraction >50%) 4
• History of malignancy (requires careful consideration) 9, 10

Ongoing Monitoring Requirements

During Treatment

• Periodic history and physical examination 4
• Annual tuberculin skin testing (consider) 4
• Periodic CBC and LFTs 4, 9
• Monitor for hepatitis B reactivation in carriers 6
• Immediate evaluation if signs/symptoms of infection, lupus-like syndrome, cytopenias, or neurological symptoms develop 1

Vaccination Status

Update before starting treatment:

• Pneumococcus, influenza, COVID-19, herpes zoster, RSV, HPV 3
• Avoid live vaccines during treatment 4, 1

Expected Efficacy

Psoriasis

• 80% achieve PASI-75 at 12 weeks 4
• 68% maintain PASI-75 at 60 weeks 4
• Response evident within 1-2 weeks 2

Rheumatoid Arthritis

• 57% achieve ACR20 response at 24 weeks 11
• Methotrexate combination increases efficacy (reduces adalimumab clearance by 44%) 1

Crohn's Disease

The AGA strongly recommends adalimumab as first-line therapy for moderate-to-severe Crohn's disease 3.

Common Adverse Effects

Most common (>10%): Injection site reactions (12-37%), upper respiratory infections, sinusitis, headache, rash 1, 9, 10

Serious but rare:

• Serious infections (2-fold increased risk): tuberculosis reactivation, opportunistic infections, Legionella 6, 9, 10
• Malignancies (unclear causal relationship—psoriasis itself increases risk) 9, 10
• Demyelinating disease (new onset or exacerbation) 9, 7, 8
• Lupus-like syndrome (reversible upon discontinuation) 4, 9
• Cytopenias/pancytopenia 4, 9
• Congestive heart failure (new onset or worsening) 4
• Paradoxical psoriasis or other autoimmune blistering diseases 12

Overall adverse event rate: 245-399 per 100 patient-years; serious AEs: 6-23 per 100 patient-years 10

Combination Therapy Considerations

With Methotrexate

Strongly consider adding methotrexate 2, 13:

• Reduces immunogenicity (anti-adalimumab antibody formation)
• Increases efficacy by reducing adalimumab clearance 1
• Particularly important if psoriatic arthritis is present 2

With Topicals

Can combine with high-potency corticosteroids ± vitamin D analogues to augment efficacy (Strength B recommendation) 2

Special Populations

Pregnancy

• FDA Category B 4
• Safe during first trimester 10
• Increased first-trimester miscarriage rate reported 6

Pediatrics

• Safe in children as young as 2 years (for JIA and uveitis) 14, 1
• Weight-based dosing required 14, 1

Elderly

• Safe for elderly patients 10
• Lower clearance with increasing age 1

Critical Warnings

Discontinue immediately if:

• Serious infection develops 1
• Signs of tuberculosis or opportunistic infection 4
• Neurological symptoms suggesting demyelination 7, 8
• Symptoms of lupus, significant cytopenias, or worsening heart failure 1

Do not restart without specialist consultation if demyelinating disease develops—these patients may require disease-modifying therapy like rituximab or ocrelizumab 7, 8.

Drug Survival and Long-Term Use

Adalimumab demonstrates favorable drug survival compared to other biologics, with sustained efficacy up to 3 years in clinical trials 15. No rebound occurs upon discontinuation, though response rates may be lower upon restarting 4, 13.